vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $962.7M, roughly 1.6× APTARGROUP, INC.). APTARGROUP, INC. runs the higher net margin — 7.7% vs -13.6%, a 21.3% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs -5.3%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $96.0M). Over the past eight quarters, APTARGROUP, INC.'s revenue compounded faster (2.6% CAGR vs -3.6%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
ATR vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $1.5B |
| Net Profit | $74.3M | $-205.0M |
| Gross Margin | — | 49.2% |
| Operating Margin | 11.0% | -9.8% |
| Net Margin | 7.7% | -13.6% |
| Revenue YoY | 13.5% | -5.3% |
| Net Profit YoY | -26.4% | -288.1% |
| EPS (diluted) | $1.13 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | $1.5B | ||
| Q3 25 | $961.1M | $1.6B | ||
| Q2 25 | $966.0M | $1.6B | ||
| Q1 25 | $887.3M | $1.5B | ||
| Q4 24 | $848.1M | $1.6B | ||
| Q3 24 | $909.3M | $1.6B | ||
| Q2 24 | $910.1M | $1.6B | ||
| Q1 24 | $915.4M | $1.6B |
| Q4 25 | $74.3M | $-205.0M | ||
| Q3 25 | $127.9M | $160.0M | ||
| Q2 25 | $111.7M | $145.0M | ||
| Q1 25 | $78.8M | $87.0M | ||
| Q4 24 | $100.9M | $109.0M | ||
| Q3 24 | $100.0M | $359.0M | ||
| Q2 24 | $90.5M | $195.0M | ||
| Q1 24 | $83.1M | $201.0M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | 11.0% | -9.8% | ||
| Q3 25 | 14.2% | 15.2% | ||
| Q2 25 | 14.9% | 14.4% | ||
| Q1 25 | 12.8% | 6.7% | ||
| Q4 24 | 14.2% | 8.1% | ||
| Q3 24 | 15.2% | 13.1% | ||
| Q2 24 | 13.8% | 14.6% | ||
| Q1 24 | 12.2% | 14.5% |
| Q4 25 | 7.7% | -13.6% | ||
| Q3 25 | 13.3% | 10.0% | ||
| Q2 25 | 11.6% | 9.1% | ||
| Q1 25 | 8.9% | 5.8% | ||
| Q4 24 | 11.9% | 6.8% | ||
| Q3 24 | 11.0% | 22.7% | ||
| Q2 24 | 9.9% | 12.1% | ||
| Q1 24 | 9.1% | 12.4% |
| Q4 25 | $1.13 | $-0.78 | ||
| Q3 25 | $1.92 | $0.61 | ||
| Q2 25 | $1.67 | $0.56 | ||
| Q1 25 | $1.17 | $0.33 | ||
| Q4 24 | $1.48 | $0.42 | ||
| Q3 24 | $1.48 | $1.38 | ||
| Q2 24 | $1.34 | $0.75 | ||
| Q1 24 | $1.23 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $574.0M |
| Total DebtLower is stronger | $1.1B | $8.6B |
| Stockholders' EquityBook value | $2.7B | $752.0M |
| Total Assets | $5.3B | $12.9B |
| Debt / EquityLower = less leverage | 0.43× | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | $574.0M | ||
| Q3 25 | $264.8M | $672.0M | ||
| Q2 25 | $169.8M | $599.0M | ||
| Q1 25 | $136.8M | $547.0M | ||
| Q4 24 | $226.2M | $675.0M | ||
| Q3 24 | $327.9M | $763.0M | ||
| Q2 24 | $223.9M | $704.0M | ||
| Q1 24 | $201.1M | $575.0M |
| Q4 25 | $1.1B | $8.6B | ||
| Q3 25 | $546.0M | $8.8B | ||
| Q2 25 | $535.1M | $8.9B | ||
| Q1 25 | $561.2M | $9.0B | ||
| Q4 24 | $688.1M | $8.9B | ||
| Q3 24 | $822.7M | $8.7B | ||
| Q2 24 | $681.5M | $8.7B | ||
| Q1 24 | $680.4M | $8.7B |
| Q4 25 | $2.7B | $752.0M | ||
| Q3 25 | $2.8B | $906.0M | ||
| Q2 25 | $2.7B | $733.0M | ||
| Q1 25 | $2.5B | $542.0M | ||
| Q4 24 | $2.5B | $472.0M | ||
| Q3 24 | $2.5B | $493.0M | ||
| Q2 24 | $2.4B | $144.0M | ||
| Q1 24 | $2.3B | $48.0M |
| Q4 25 | $5.3B | $12.9B | ||
| Q3 25 | $5.1B | $13.6B | ||
| Q2 25 | $4.9B | $13.5B | ||
| Q1 25 | $4.5B | $13.2B | ||
| Q4 24 | $4.4B | $13.1B | ||
| Q3 24 | $4.6B | $12.8B | ||
| Q2 24 | $4.5B | $12.2B | ||
| Q1 24 | $4.4B | $11.9B |
| Q4 25 | 0.43× | 11.49× | ||
| Q3 25 | 0.20× | 9.74× | ||
| Q2 25 | 0.20× | 12.14× | ||
| Q1 25 | 0.22× | 16.52× | ||
| Q4 24 | 0.28× | 18.81× | ||
| Q3 24 | 0.32× | 17.75× | ||
| Q2 24 | 0.28× | 60.11× | ||
| Q1 24 | 0.29× | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $141.0M |
| Free Cash FlowOCF − Capex | $96.9M | $96.0M |
| FCF MarginFCF / Revenue | 10.1% | 6.4% |
| Capex IntensityCapex / Revenue | 9.0% | 3.0% |
| Cash ConversionOCF / Net Profit | 2.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | $141.0M | ||
| Q3 25 | $177.6M | $264.0M | ||
| Q2 25 | $126.0M | $220.0M | ||
| Q1 25 | $82.7M | $75.0M | ||
| Q4 24 | $178.2M | $390.0M | ||
| Q3 24 | $229.3M | $141.0M | ||
| Q2 24 | $143.6M | $332.0M | ||
| Q1 24 | $92.3M | $76.0M |
| Q4 25 | $96.9M | $96.0M | ||
| Q3 25 | $114.3M | $218.0M | ||
| Q2 25 | $62.5M | $181.0M | ||
| Q1 25 | $25.9M | $43.0M | ||
| Q4 24 | $112.2M | $335.0M | ||
| Q3 24 | $162.7M | $99.0M | ||
| Q2 24 | $75.4M | $300.0M | ||
| Q1 24 | $16.7M | $30.0M |
| Q4 25 | 10.1% | 6.4% | ||
| Q3 25 | 11.9% | 13.6% | ||
| Q2 25 | 6.5% | 11.4% | ||
| Q1 25 | 2.9% | 2.8% | ||
| Q4 24 | 13.2% | 21.0% | ||
| Q3 24 | 17.9% | 6.3% | ||
| Q2 24 | 8.3% | 18.7% | ||
| Q1 24 | 1.8% | 1.8% |
| Q4 25 | 9.0% | 3.0% | ||
| Q3 25 | 6.6% | 2.9% | ||
| Q2 25 | 6.6% | 2.4% | ||
| Q1 25 | 6.4% | 2.1% | ||
| Q4 24 | 7.8% | 3.5% | ||
| Q3 24 | 7.3% | 2.7% | ||
| Q2 24 | 7.5% | 2.0% | ||
| Q1 24 | 8.3% | 2.8% |
| Q4 25 | 2.47× | — | ||
| Q3 25 | 1.39× | 1.65× | ||
| Q2 25 | 1.13× | 1.52× | ||
| Q1 25 | 1.05× | 0.86× | ||
| Q4 24 | 1.77× | 3.58× | ||
| Q3 24 | 2.29× | 0.39× | ||
| Q2 24 | 1.59× | 1.70× | ||
| Q1 24 | 1.11× | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
OGN
Segment breakdown not available.
